scholarly journals Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma

2017 ◽  
Vol 86 ◽  
pp. 115-124 ◽  
Author(s):  
Teresa M. Petrella ◽  
Caroline Robert ◽  
Erika Richtig ◽  
Wilson H. Miller ◽  
Giuseppe V. Masucci ◽  
...  
Keyword(s):  
Patient Reported Outcomes ◽  
Advanced Melanoma ◽  
Randomised Study ◽  
Patient Reported

scholarly journals The Role of Patient-Reported Outcomes in Drug-Coverage Decisions for New Agents with Advanced Melanoma Indication

2016 ◽  
Vol 19 (3) ◽  
pp. A128
Author(s):  
H Beyhaghi ◽  
M Parente-Ribes ◽  
E Piault-Louis ◽  
A Campbell ◽  
K Bartley
Keyword(s):  
Patient Reported Outcomes ◽  
Advanced Melanoma ◽  
Drug Coverage ◽  
New Agents ◽  
Patient Reported

Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial)

2021 ◽  
Vol 155 ◽  
pp. 179-190
Author(s):  
Giuseppe Lombardi ◽  
Paola Del Bianco ◽  
Alba A. Brandes ◽  
Marica Eoli ◽  
Roberta Rudà ◽  
...  
Keyword(s):  
Phase Ii ◽  
Patient Reported Outcomes ◽  
Randomised Study ◽  
Patient Reported

scholarly journals Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Stéphane Dalle ◽  
Laurent Mortier ◽  
Pippa Corrie ◽  
Michal Lotem ◽  
Ruth Board ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Real World ◽  
Patient Reported Outcomes ◽  
Advanced Melanoma ◽  
Image Study ◽  
Patient Reported ◽  
Treatment Naïve ◽  
Systemic Therapies

Abstract Background Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking. We present long-term outcomes from the IMAGE study (NCT01511913) in patients receiving ipilimumab and/or non-ipilimumab (any approved treatment other than ipilimumab) systemic therapies. Methods IMAGE was a multinational, prospective, observational study assessing adult patients with advanced melanoma treated with ipilimumab or non-ipilimumab systemic therapies between June 2012 and March 2015 with ≥3 years of follow-up. Adjusted OS curves based on multivariate Cox regression models included covariate effects. Safety and patient-reported outcomes were assessed. Results Among 1356 patients, 1094 (81%) received ipilimumab and 262 (19%) received non-ipilimumab index therapy (systemic therapy [chemotherapy, anti–programmed death 1 antibodies, or BRAF ± MEK inhibitors], radiotherapy, and radiosurgery). In the overall population, median age was 64 years, 60% were male, 78% were from Europe, and 78% had received previous treatment for advanced melanoma. In the ipilimumab-treated cohort, 780 (71%) patients did not receive subsequent therapy (IPI-noOther) and 314 (29%) received subsequent non-ipilimumab therapy (IPI-Other) on study. In the non-ipilimumab–treated cohort, 205 (78%) patients remained on or received other subsequent non-ipilimumab therapy (Other-Other) and 57 (22%) received subsequent ipilimumab therapy (Other-IPI) on study. Among 1151 patients who received ipilimumab at any time during the study (IPI-noOther, IPI-Other, and Other-IPI), 296 (26%) reported CTCAE grade ≥ 3 treatment-related adverse events, most occurring in year 1. Ipilimumab-treated and non-ipilimumab–treated patients who switched therapy (IPI-Other and Other-IPI) had longer OS than those who did not switch (IPI-noOther and Other-Other). Patients with prior therapy who did not switch therapy (IPI-noOther and Other-Other) showed similar OS. In treatment-naive patients, those in the IPI-noOther group tended to have longer OS than those in the Other-Other group. Patient-reported outcomes were similar between treatment cohorts. Conclusions With long-term follow-up (≥ 3 years), safety and OS in this real-world population of patients treated with ipilimumab 3 mg/kg were consistent with those reported in clinical trials. Patient-reported quality of life was maintained over the study period. OS analysis across both pretreated and treatment-naive patients suggested a beneficial role of ipilimumab early in treatment. Trial registration ClinicalTrials.gov, NCT01511913. Registered January 19, 2012 – Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT01511913

P048 QUALITY OF LIFE AND OTHER PATIENT REPORTED OUTCOMES IN PATIENTS WITH POUCHITIS

2020 ◽  
Vol 158 (3) ◽  
pp. S107
Author(s):  
Edward Barnes ◽  
Millie Long ◽  
Laura Raffals ◽  
Xian Zhang ◽  
Anuj Vyas ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Patient Reported Outcomes ◽  
Patient Reported

Erfassung und Nutzen von „Patient Reported Outcomes“ (PRO) in der stationären onkologischen Routineversorgung

2014 ◽  
Vol 15 (03) ◽  
Author(s):  
M Radloff ◽  
J Schmitt ◽  
M Eberlein-Gonska ◽  
M Schuler ◽  
T Petzold ◽  
...  
Keyword(s):  
Patient Reported Outcomes ◽  
Patient Reported
Sign in / Sign up

Export Citation Format

Share Document